Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

2012 • 16,041 citations

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

1999 • 2,553 citations

Global Initiative for Chronic Obstructive Lung Disease

2002 • 1,906 citations

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

2007 • 1,349 citations

Outcomes for COPD pharmacological trials: from lung function to biomarkers

2008 • 817 citations

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

2013 • 504 citations

Minimal Clinically Important Differences in COPD Lung Function

2005 • 442 citations

Dual bronchodilation with QVA149versussingle bronchodilator therapy: the SHINE study

2013 • 370 citations

Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease

2010 • 347 citations

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD

2005 • 342 citations

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study

2012 • 303 citations

Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD

2006 • 284 citations

Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol versus twice-daily formoterol in COPD

2010 • 270 citations

Once-daily indacaterolversustwice-daily salmeterol for COPD: a placebo-controlled comparison

2010 • 212 citations

Efficacy and safety of NVA237versusplacebo and tiotropium in patients with COPD: the GLOW2 study

2012 • 207 citations

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

2011 • 179 citations

The MCID of the Transition Dyspnea Index is a Total Score of One Unit

2005 • 177 citations

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison

2012 • 154 citations

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

2013 • 154 citations

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

2011 • 139 citations

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

2012 • 125 citations

Patient-Reported Dyspnea in COPD Reliability and Association With Stage of Disease

2009 • 99 citations

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study

2011 • 96 citations

Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial

2008 • 91 citations

Development of Self‐Administered Versions of Modified Baseline and Transition Dyspnea Indexes in COPD

2004 • 75 citations

Validity and Responsiveness of the Self-Administered Computerized Versions of the Baseline and Transition Dyspnea Indexes

2007 • 48 citations

PRS54 Acceptability of the Self-Administered Computerized (Sac) Versions of the Baseline/Transition Dyspnea Indexes (Bdi/Tdi) for Patients with Copd from Seven Countries

2012 • 1 citations